Several questions about the origin and development of human neoplasms can be investigated by studying tumours which arise in subjects who have two or more genetically distinct types of cells. For example, if two cell types are present in normal tissues, but the tumour contains only one type, clonal origin is suggested. Similarly, the detection of both cell types in a neoplasm suggests multicellular origin. Selected studies of tumours from human females whose cellular mosaicism is governed by X-chromosome inactivation are reviewed in this communication. A more extensive review is published elsewhere (Fialkow, 1972) .
In accordance with the inactive-X (Lyon) hypothesis, somatic cells in females have only one of their two X chromosomes active. The initial choice in embryogenesis as to which X chromosome is to be inactive in a given cell is probably random; however, once made it is fixed not only for that cell but for all its descendants. Thus, females heterozygous at a locus on the X chromosome such as the one for glucose-6-phosphate dehydrogenase (G-6-PD) have two types of cell. If, for example, the subject carries a gene for the usual type of G-6-PD (GdB) on one X chromosome and a common variant gene such as Gd A or GdA-on the other, one population of cells produces G-6-PD type A or A-, and the other G-6-PD type B (Davidson, Nitowsky, and Childs, 1963; DeMars and Nance, 1964 The first application of the G-6-PD system to the 11 study of tumours was made by Linder and Gartler (1965a) in an investigation of heterozygotes with leiomyomas of the uterus. Normal uterine muscle adjacent to the tumours had both A and B enzyme types, but only one type was present in each tumour. Thus far single enzyme phenotypes have been reported for 184 of 185 non-necrotic tumours dissected free of the surrounding myometrium (see Fialkow, 1972 (Linder and Gartler, 1965a We have applied a similar experimental approach to the study of chronic myelocytic leukaemia. The first question we explored is, Does chronic myelocytic leukaemia have a clonal origin? Since this disease involves blood cells, cultured skin fibroblasts derived from females with the disease were studied to determine whether the subjects were G-6-PD heterozygotes. In our initial investigation, three GdB/GdA females with chronic myelocytic leukaemia were ascertained (Fialkow, Gartler, and Yoshida, 1967) . One of these patients was from Mozambique and the other two from the United States. Although both A and B enzyme types were present in skin fibroblasts, preparations derived from millions of chronic myelocytic leukaemia blood granulocytes contained only a single enzyme type.
In contrast to the findings in chronic myelocytic leukaemia, 34 subjects without leukaemia who had both A and B enzymes in skin always displayed double enzyme phenotypes in blood granulocytes (Fialkow, 1973) . Therefore, the single enzyme phenotypes in chronic myelocytic leukaemia must be related to the disease and most likely reflect a clonal origin for the condition. Leukaemia cells from the first three patients studied showed only type A enzyme (Fialkow et al, 1967) , but in a subsequently studied patient, the single enzyme phenotype in the chronic myelocytic leukaemia granulocytes was B (Barr and Fialkow, 1973) .
Earlier studies utilizing another kind of marker, the Philadelphia' (Ph') chromosome also suggested a clonal origin for chronic myelocytic leukaemia (Nowell and Hungerford, 1960) . This abnormal chromosome number 22, which lacks about 40 % of its DNA, occurs almost exclusively in chronic myelocytic leukaemia. When present, it is generally found in most dividing marrow cells (Sandberg, Ishihara, Crosswhite, and Hauschka, 1962; (Lawler and Sanger, 1970 (Fitzgerald, Pickering, and Eiby, 1971) .
The second question we explored in the study of chronic myelocytic leukaemia is, In which type of cell does the disorder arise? Like the chronic myelocytic leukaemia granulocytes, red blood cells in the three GdB/GdA heterozygotes contained only a single enzyme type (type A) (Fialkow et al, 1967 Rastrick, Fitzgerald, and Gunz, 1968) .
Thus, G-6-PD and Ph' chromosome studies indicate that the alteration responsible for chronic myelocytic leukaemia occurs in a myeloid stem cell. However, cytologically this disease is not considered Human genetic markers as tracers of tumour histogenesis to be a stem cell leukaemia. The predominant picture in the marrow is an overabundance of myelocytes and more mature granulocytic cells. To reconcile these cytological observations with the genetic data, it seems necessary to postulate that the normal stem cell population is replaced by chronic myelocytic leukaemia stem cells, which in turn give rise to the overabundant myelocytic cells.
The third question we explored is, Does the abnormal clone persist during remission or do normal cells repopulate the marrow? Two of the Gd B/Gd A heterozygotes with chronic myelocytic leukaemia had chemotherapeutically induced remissions during which the single enzyme type persisted in peripheral blood cells (Fialkow et al, 1967) . This finding and the fact that the percentage of marrow cells with the Ph' chromosome does not decline during remission provide clear evidence that the abnormal clone persists during remission.
Another malignancy which we have studied extensively is Burkitt lymphoma. This lymphoblastoid neoplasm with a presumable viral aetiology occurs with notable frequency in young children in Africa and certain areas of New Guinea. Thirty-two of 33 tumours from 19 G-6-PD heterozygotes studied on initial presentation had single enzyme phenotypes despite the fact that normal tissues (including lymph nodes and blood lymphocytes) always had both A and B types of G-6-PD. Tumours from 11 heterozygotes were typed as B, from seven as A, and from one patient as AB (Fialkow, Klein, Gartler, and Clifford, 1970; Fialkow, Klein, Clifford, and Singh, 1973 Seven heterozygotes had two Burkitt tumours which could be studied and in all instances both tumours had the same single enzyme type (Fialkow et al, 1970; Fialkow et al, 1973) . The probability that this occurred by chance alone is less than 1 %, and it seems likely that the entire disease has a single cell origin, ie, it begins at one place in a single cell and then spreads to other parts of the body. Results of studies using another cell marker, surfaceassociated immunoglobulin, are in accord with this view arising at a site far removed from the original site of a neoplasm after a relatively long remission has been studied in a G-6-PD heterozygote (Fialkow, Klein, and Clifford, 1972a) . Before therapy the patient's ovarian neoplasm was typed as B. Three months after institution of therapy she was judged to be in total remission but one month later disease recurred in the left parotid. That tumour was also typed as B. Ten weeks later a tumour was noted in the left orbit for the first time, and, unlike the first two neoplasms, it had an A phenotype. This observation strongly suggests that late exacerbations of disease after total tumour regression may be due to new occurrence of disease rather than to reemergence of the original malignant cell lines. Results obtained using cell surface-associated IgM as a marker support this suggestion .
Study of carcinomas is difficult because the tumour tissue is generally contaminated with non-neoplastic constituents such as blood cells, stroma, and normal tissue. When account is taken of this, data in carcinoma of the postnasal space and other sites in the head and neck are compatible with clonal origins for these malignancies (Fialkow, Martin, Klein, Clifford, and Singh, 1972b) . However, it seems likely that at least one carcinoma of the colon (Beutler, Collins, and Irwin, 1967) and perhaps some cases of carcinoma of the cervix have multicellular origins (Smith, Townsend, and Sparkes, 1971a ; but see also Park and Jones, 1968) .
Underwhatcircumstances might oneexpect tumours to arise from multiple cells? This type or origin implies that a relatively large number of cells is innately susceptible and/or that the external aetiological agent is one that affects many cells simultaneously. For example, a multicellular origin could be found for tumours caused by viral transformation of multiple adjacent cells. The data suggest that this is not the case in Burkitt lymphoma, the malignancy in man for which there is the most evidence, albeit indirect, of a viral aetiology. Furthermore, study of the one human neoplasm with a proven viral cause, Verruca vulgaris (the common wart), suggests a clonal origin (Murray, Hobbs, and Payne, 1971) . Only one type of G-6-PD was found in single warts from 6 GdB/GA heterozygotes. These data imply that the development of a mature wart does not depend upon viral spread from cell to cell and that a clonal origin is likely.
Hormones could also bring about the develop-ment of tumours from more than a single cell since presumably a whole organ would be exposed to the oncogenic environment. Thyroid adenomas from five patients (Linder, 1969; Fialkow et al, 1972b ) and thyroid carcinomas from two patients (Fialkow et al, 1972b) (McCurdy, 1968; Smith, Townsend, and Sparkes, 1971b (Fialkow, Sagebiel, Gartler, and Rimoin, 1971 (Gartler, Ziprkowski, Krakowski, Ezra, Szeinberg, and Adam, 1966 
